Nkarta (NASDAQ:NKTX) Shares Down 5.7%

Nkarta, Inc. (NASDAQ:NKTX - Get Free Report)'s share price was down 5.7% on Tuesday . The stock traded as low as $10.11 and last traded at $10.20. Approximately 68,322 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 2,093,983 shares. The stock had previously closed at $10.82.

Wall Street Analyst Weigh In

Several analysts have weighed in on NKTX shares. Canaccord Genuity Group lifted their price objective on shares of Nkarta from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday, March 26th. Needham & Company LLC restated a "buy" rating and issued a $15.00 target price on shares of Nkarta in a research report on Friday, March 22nd. Raymond James restated an "outperform" rating and issued a $16.00 target price (up from $13.00) on shares of Nkarta in a research report on Friday, March 22nd. Mizuho dropped their target price on shares of Nkarta from $31.00 to $25.00 and set a "buy" rating for the company in a research report on Friday, March 22nd. Finally, HC Wainwright dropped their target price on shares of Nkarta from $22.00 to $20.00 and set a "buy" rating for the company in a research report on Friday, March 22nd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $17.83.

Nkarta Stock Performance

The company has a market capitalization of $488.76 million, a P/E ratio of -4.12 and a beta of 0.71. The firm's fifty day moving average is $11.08 and its 200-day moving average is $6.19.

Nkarta (NASDAQ:NKTX - Get Free Report) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.05. As a group, analysts expect that Nkarta, Inc. will post -2.34 EPS for the current fiscal year.

Insider Activity at Nkarta

In other Nkarta news, insider David Shook sold 3,552 shares of the business's stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $8.74, for a total transaction of $31,044.48. Following the sale, the insider now directly owns 114,980 shares of the company's stock, valued at approximately $1,004,925.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Nkarta news, insider David Shook sold 3,552 shares of the business's stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $8.74, for a total transaction of $31,044.48. Following the sale, the insider now directly owns 114,980 shares of the company's stock, valued at approximately $1,004,925.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James Trager sold 4,143 shares of the business's stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $12.00, for a total transaction of $49,716.00. Following the sale, the insider now directly owns 149,415 shares in the company, valued at $1,792,980. The disclosure for this sale can be found here. In the last three months, insiders have sold 17,392 shares of company stock valued at $165,512. 5.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Nkarta

Several large investors have recently modified their holdings of NKTX. Sei Investments Co. acquired a new stake in shares of Nkarta during the second quarter worth $27,000. Natixis acquired a new stake in shares of Nkarta during the fourth quarter worth $28,000. Advisor Group Holdings Inc. increased its position in shares of Nkarta by 13,661.1% during the fourth quarter. Advisor Group Holdings Inc. now owns 4,954 shares of the company's stock worth $29,000 after buying an additional 4,918 shares during the period. Bourgeon Capital Management LLC acquired a new stake in shares of Nkarta during the fourth quarter worth $30,000. Finally, American Century Companies Inc. increased its position in shares of Nkarta by 59.9% during the third quarter. American Century Companies Inc. now owns 21,817 shares of the company's stock worth $30,000 after buying an additional 8,177 shares during the period. 80.54% of the stock is currently owned by institutional investors and hedge funds.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.